# Pasithea Therapeutics (KTTA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/KTTA
## Company Profile
- Ticker: KTTA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 0.58 USD
- Market cap: 21552318.96 USD
- Last updated: 2026-09-04
## Business Overview
Pasithea Therapeutics is a biotechnology company focused on neuropsychiatric disorders and inflammation-linked biology. Its story centers on developing treatments for difficult CNS conditions with limited effective options.
## Why The Stock Is Moving

The latest monitored headline was “Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences”. KTTA was little changed in the corresponding trading session, closing at $0.5800 on Sep 4, 2026.

## Geographic Base

Pasithea is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotechnology with a neuroscience angle.

## Business Model

The company depends on clinical progress, translational validation, and capital efficiency. Investors generally watch early data, program resets, and whether the company can maintain a coherent development strategy.

## Landscape Position

Pasithea occupies a speculative neuroscience niche within biotech. The stock tends to be driven by the market's willingness to underwrite a narrow CNS thesis.

## Future Catalysts

- Pasithea’s catalysts are oncology and CNS programs, along with any strategic step that clarifies what the company is really building. The stock remains highly dependent on a cleaner path.

## Recent News
- 2026-09-03 20:05 EST — [Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-participation-in-two-september-2026-investor-con-bb3e0469) — Source: Pasithea Therapeutics
- 2026-07-21 11:00 EST — [Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-presentation-of-pas-004-data-to-european-society-99db076a) — Source: Pasithea Therapeutics
- 2026-07-08 11:02 EST — [Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-participation-in-b-riley-securities-mind-muscle--c2ef8757) — Source: Pasithea Therapeutics
- 2026-06-30 11:00 EST — [Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-positive-interim-phase-1-advanced-cancer-study-d-e066723c) — Source: Pasithea Therapeutics
- 2026-06-16 11:00 EST — [Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-amendments-to-clinical-study-protocol-for-phase--66feaf01) — Source: Pasithea Therapeutics